Abstrakt

A large number of studies have pointed to the relations between blood levels of 25-hydroxy vitamin D with cancer incidence and survival. The phenomenon of the multidirectional activity of vitamin D is possibly due to the presence of VDR in most nonskeletal human cells, including cancer cells. A wide range of the genes regulated by VDR are related with cell proliferation, apoptosis, differentiation, angiogenesis and metastasis. In some preclinical studies, colon, lung and BC have all demonstrated downregulation of VDR expression as compared to normal cells, and well-differentiated tumors have shown more VDR expression when compared to their poorly differentiated counterparts. Generally, higher tumor VDR expression has been noted as correlating with better prognosis in cancer patients. However, vitamin D pathway genetic polymorphisms also may influence cancer risk. VDR polymorphisms have received the most attention, but this influence has also been observed in genes related to vitamin D metabolism or signalling, such as: CYP27B1, CYP24A1, VDBP or RXRA. Even though the associations between most of them and cancers were not significant, some studies show that VDR polymorphisms may be a better or poor prognostic factor to assess the risk of cancer. The aim of this paper was to present the molecular pathways affected by vitamin D, which are included in carcinogenesis. The literature survey comprised of research compiled from mostly the last five years and it proves vitamin D as the most phenomenal among other vitamins.

Przypisy

• 1. Abbas S., Nieters A., Linseisen J., Slanger T., Kropp S., MutschelknaussE.J., Flesch-Janys D., Chang-Claude J.: Vitamin D receptor genepolymorphisms and haplotypes and postmenopausal breast cancerrisk. Breast Cancer Res., 2008; 10: R31
  Google Scholar
• 2. Alimirah F., Peng X., Gupta A., Yuan L., Welsh J., Cleary M., MehtaR.G.: Crosstalk between the vitamin D receptor (VDR) and miR-214in regulating SuFu, a hedgehog pathway inhibitor in breast cancercells. Exp. Cell Res., 2016; 349: 15–22
  Google Scholar
• 3. Anisiewicz A., Pawlik A., Filip-Psurska B., Turlej E., Dzimira S.,Milczarek M., Gdesz K., Papiernik D., Jarosz J., Kłopotowska D., KutnerA., Mazur A., Wietrzyk J.: Unfavorable effect of calcitriol and itslow-calcemic analogs on metastasis of 4T1 mouse mammary glandcancer. Int. J. Oncol., 2018; 52: 103–126
  Google Scholar
• 4. Arem H., Yu K., Xiong X., Moy K., Freedman N.D., Mayne S.T.,AlbanesD., Arslan A.A., Austin M., Bamlet W.R., Beane-Freeman L.,Bracci P., Canzian F., Cotterchio M., Duell E.J., et al.: Vitamin D metabolicpathwaygenes and pancreatic cancer risk. PLoS One, 2015;10: e0117574
  Google Scholar
• 5. Baykan O., Akgul M., Uren N., Yaman A., Tinay I., Erqul E., Sazci A.,Turkeri L., Haklar G.: The relationship between urothelial type bladdercancer, plasma 25-hydroxyvitamin D levels, and vitamin D receptorApaI BsmI FokI, and TaqI polymorphisms. Clin. Lab., 2019; 65(4)
  Google Scholar
• 6. Beysel S., Eyerci N., Pinarli F.A., Apaydin M., Kizilgul M., CaliskanM., Ozcelik O., Kan S., Cakal E.: VDR gene FokI polymorphism as apoor prognostic factor for papillary thyroid cancer. Tumour Biol.,2018; 40: 1010428318811766
  Google Scholar
• 7. Boonstra A., Barrat F.J., Crain C., Heath V.L., Savelkoul H.F., O’GarraA.: 1α,25-dihydroxyvitamin D3 has a direct effect on naive CD4+T cells to enhance the development of Th2 cells. J. Immunol., 2001;167: 4974–4980
  Google Scholar
• 8. Chandler P.D., Tobias D.K., Wang L., Smith-Warner S.A., ChasmanD.I., Rose L., Giovanucci E.L., Buring J.E., Ridker P.M., CookN.R., Manson J.E., Sesso H.D.: Association between vitamin D geneticrisk score and cancer risk in a large cohort of U.S. women.Nutrients, 2018; 10: E55
  Google Scholar
• 9. Chen W.Y., Bertone-Johnson E.R., Hunter D.J., Willet W.C., HankinsonS.E.: Associations between polymorphisms in the vitaminD receptor and breast cancer risk. Cancer Epidemiol. BiomarkersPrev., 2005; 14: 2335–2339
  Google Scholar
• 10. Chiang K.C., Yeh T.S., Chen S.C., Pang J.H., Yeh C.N., Hsu J.T.,Chen L.W., Kuo S.F., Takano M., Kittaka A., Chen T.C., Sun C.C., JuangH.H.: The vitamin D analog, MART-10, attenuates triple negative breastcancer cells metastatic potential. Int. J. Mol. Sci., 2016; 17: E606
  Google Scholar
• 11. Cho Y.A., Lee J., Oh J.H., Chang H.J., Sohn D.K., Shin A., Kim J.:Vitamin D receptor FokI polymorphism and the risk of colorectalcancer, inflammatory bowel disease, and colorectal adenoma. Sci.Rep., 2018; 8: 12899
  Google Scholar
• 12. Chung I., Guangzhou H., Seshadri M., Gillard B.M., Yu W., FosterB.A., Trump D.L., Johnson C.S.: Role of vitamin D receptor in theantiproliferative effects of calcitriol in tumor-derived endothelialcells and tumor angiogenesis in vivo. Cancer Res., 2009; 69: 967–975
  Google Scholar
• 13. Clendenen T.V., Ge W., Koenig K.L., Axelsson T., Liu M., AfanasyevaY., Andersson A., Arslan A.A., Chen Y., Hallmans G., Lenner P.,Kirchhoff T., Lundin E., Shore R.E., Sund M., et al.: Genetic polymorphismsin vitamin D metabolism and signaling genes and risk of breastcancer: a nested case-control study. PLoS One, 2015; 10: e0140478
  Google Scholar
• 14. Crew K.D.: Vitamin D: are we ready to supplement for breastcancer prevention and treatment? ISRN Oncol., 2013; 2013: 483687
  Google Scholar
• 15. de La Puente-Yagüe M., Cuadrado-Cenzual M.A., Ciudad-CabañasM.J., Hernández-Cabria M., Collado-Yurrita L.: Vitamin D: and its rolein breast cancer. Kaohsiung J. Med. Sci., 2018; 34: 423–427
  Google Scholar
• 16. Duffy M.J., Murray A., Synnott N.C., O’Donovan N., Crown J.:Vitamin D analogues: potential use in cancer treatment. Crit. Rev.Oncol. Hematol., 2017; 112: 190–197
  Google Scholar
• 17. Eom S.Y., Yim D.H., Kim D.H., Yun H.Y., Song Y.J., Youn S.J., HyunT., Park J.S., Kim B.S., Kim Y.D., Kim H.: Dietary vitamin D intake andvitamin D related genetic polymorphisms are not associated withgastric cancer in a hospital-based case-control study in Korea. J.Biomed. Res., 2018; 32: 257–263
  Google Scholar
• 18. Fair A.M., Lewis T.J., Sanderson M., Dupont W.D., Fletcher S., EganK.M., Disher A.C.: Increased vitamin D and calcium intake associatedwith reduced mammographic breast density among premenopausalwomen. Nutr. Res., 2015; 35: 851–857
  Google Scholar
• 19. Gruber-Bzura B.M.: Vitamin D and influenza – prevention ortherapy? Int. J. Mol. Sci., 2018; 19: E2419
  Google Scholar
• 20. Guy M., Lowe L.C., Bretherton-Watt D., Mansi J.L., Peckitt C.,Bliss J., Wilson R.G., Thomas V., Colston K.W.: Vitamin D receptorgene polymorphisms and breast cancer risk. Clin. Cancer Res., 2004;10: 5472–5481
  Google Scholar
• 21. Heine G., Niesner U., Chang H.D., Steinmeyer A., Zügel U., ZuberbierT., Radbruch A., Worm M.: 1,25-dihydroxyvitamin D3 promotesIL-10 production in human B cells. Eur. J. Immunol., 2008;38: 2210–2218
  Google Scholar
• 22. Jeong Y., Swami S., Krishnan A.V., Wiliams J.D., Martin S., HorstR.L., Albertelli M.A., Feldman B.J., Feldman D., Diehn M.: Inhibitionof mouse breast tumor-initiating cells by calcitriol and dietary vitaminD. Mol. Cancer Ther., 2015; 14: 1951–1961
  Google Scholar
• 23. Khatun A., Fujimoto M., Kito H., Niwa S., Suzuki T., Ohya S.:Down-regulation of Ca2+ -activated K+ channel KCa 1.1 in humanbreast cancer MDA-MB-453 cells treated with vitamin D receptoragonists. Int. J. Mol. Sci., 2016; 17: 2083
  Google Scholar
• 24. Kong J., Xu F., Qu J., Wang Y., Gao M., Yu H., Qian B.: Genetic polymorphismsin the vitamin D pathway in relation to lung cancerrisk and survival. Oncotarget, 2015; 6: 2573–2582
  Google Scholar
• 25. Kowanetz M., Wu X., Lee J., Tan M., Hagenbeek T., Qu X., Yu L.,Ross J., Korsisaari N., Cao T., Bou-Reslan H., Kallop D., Weimer R.,Ludlam M.J., Kaminker J.S., et al.: Granulocyte-colony stimulatingfactor promotes lung metastasis through mobilization of Ly6G+Ly6C+granulocytes. Proc. Natl. Acad. Sci. USA, 2010; 107: 21248–21255
  Google Scholar
• 26. Köstner K., Denzer N., Müller C.S., Klein R., Tilgen W., Reichrath J.:The relevance of vitamin D receptor (VDR) gene polymorphismsforcancer: a review of the literature. Anticancer Res., 2009; 29: 3511–3536
  Google Scholar
• 27. Krishnan A.V., Trump D.L., Johnson C.S., Feldman D.: The roleof vitamin D in cancer prevention and treatment. Rheum. Dis. Clin.North Am., 2012; 38: 161–178
  Google Scholar
• 28. Lin J., Manson J.E., Lee I.M., Cook N.R., Buring J.E., Zhang S.M.:Intakes of calcium and vitamin D and breast cancer risk in women.Arch. Intern. Med., 2007; 167: 1050–1059
  Google Scholar
• 29. Lu D., Jing L., Zhang S.: Vitamin D receptor polymorphism andbreast cancer risk: A meta-analysis. Medicine, 2016; 95: e3535
  Google Scholar
• 30. Manson J.E., Cook N.R., Lee I.M., Christen W., Bassuk S.S., MoraS., Gibson H., Gordon D., Copeland T., D’Agostino D., FriedenbergG., Ridge C., Bubes V., Giovanucci E.L., Willett W.C., et al.: Vitaminsupplements and prevention of cancer and cardiovascular disease.N. Engl. J. Med., 2019; 380: 33–44
  Google Scholar
• 31. McCullough M.L., Stevens V.L., Diver W.R., Feigelson H.S., RodriguezC., Bostick R.M., Thun M.J., Calle E.E.: Vitamin D pathway genepolymorphisms, diet, and risk of postmenopausal breast cancer:A nested case-control study. Breast Cancer Res., 2007; 9: R9
  Google Scholar
• 32. Mohamed A.A., Aref A.M., Talima S.M., A Elshimy R.A., GergesS.S., Meghed M., Zahran F.E., El-Adawy E.H., Abd-Elsalam S.: Associationof serum level of vitamin D and VDR polymorphism Fok1 withthe risk or survival of pancreatic cancer in Egyptian population.Indian J. Cancer, 2019; 56: 130–134
  Google Scholar
• 33. Moukayed M., Grant W.B.: The roles of UVB and vitamin D inreducing risk of cancer incidence and mortality: a review of theepidemiology, clinical trials, and mechanisms. Rev. Endocr. Metab.Disord., 2017; 18: 167–182
  Google Scholar
• 34. O’Brien K.M, Sandler D.P, Xu Z., Kinyamu H.K., Taylor J.A., WeinbergC.R.: Vitamin D, DNA methylation, and breast cancer. BreastCancer Res., 2018; 20: 70
  Google Scholar
• 35. Pandolfi F., Franza L., Mandolini C., Conti P.: Immune modulationby vitamin D: Special emphasis on its role on prevention andtreatment of cancer. Clin. Ther., 2017; 39: 884–893
  Google Scholar
• 36. Pawlik A., Anisiewicz A., Filip-Psurska B., Nowak M., Turlej E.,Trynda J., Banach J., Gretkierewicz P., Wietrzyk J.: Calcitriol and itsanalogs establish the immunosuppressive microenvironment thatdrives metastasis in 4T1 mouse mammary gland cancer. Int. J. Mol.Sci., 2018; 19: E2116
  Google Scholar
• 37. Peterlik M., Grant W.B., Cross H.S.: Calcium, vitamin D and cancer.Anticancer Res., 2009; 29: 3687–3698
  Google Scholar
• 38. Raimondi S., Johansson H., Maisonneuve P., Gandini S.: Reviewand meta-analysis on vitamin D receptor polymorphisms and cancerrisk. Carcinogenesis, 2009; 30: 1170–1180
  Google Scholar
• 39. Reimers L.L., Crew K.D., Bradshaw P.T., Santella R.M., Steck S.E.,Sirosh I., Terry M.B., Hershman D.L., Shane E., Cremers S., DworakowskiE., Teitelbaum S.L., Neugut A.I., Gammon M.D.: Vitamin D-relatedgene polymorphisms, plasma 25-hydroxyvitamin D, and breastcancer risk. Cancer Causes Control., 2015; 26: 187–203
  Google Scholar
• 40. Santos J.M., Khan Z.S., Munir M.T., Tarafdar K., Rahman S.M.,Hussain F.: Vitamin D3 decreases glycolysis and invasiveness, andincreases cellular stiffness in breast cancer cells. J. Nutr. Biochem.,2018; 53: 111–120
  Google Scholar
• 41. Vidigal V.M., Silva T.D., de Oliveira J., Pimenta C.A., Felipe A.V.,Forones N.M.: Genetic polymorphisms of vitamin D receptor (VDR),CYP27B1 and CYP24A1 genes and the risk of colorectal cancer. Int.J. Biol. Markers, 2017; 32: e224–e230
  Google Scholar
• 42. Williams J.D., Aggarwal A., Swami S., Krishnan A.V., Ji L., AlbertelliM.A., Feldman B.J.: Tumor autonomous effects of vitamin Ddeficiency promote breast cancer metastasis. Endocrinology, 2016;157: 1341–1347
  Google Scholar
• 43. Yu Z.H., Chen M., Zhang Q.Q., Hu X.: The association of vitamin Dreceptor gene polymorphism with lung cancer risk: an update meta-analysis. Comb. Chem. High Throughput Screen, 2018; 21: 704–710
  Google Scholar
• 44. Zeichner S.B., Koru-Sengul T., Shah N., Liu Q., Markward N.J.,Montero A.J., Glück S., Silva O., Ahn E.R.: Improved clinical outcomesassociated with vitamin D supplementation during adjuvantchemotherapy in patients with HER2+ nonmetastatic breast cancer.Clin. Breast Cancer, 2015; 15: e1–e11
  Google Scholar

Pełna treść artykułu